Medpace Holdings opened at $677.85, in line with its previous close of $677.56. In the last trading session, the stock traded between $650.95 and $677.85. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Medpace Holdings is now worth
$ 288.01
giving a profit of
$ 188.01 (188.01%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
33.33%
Hold
66.67%
Sell
0%
Markets Today
Today's Change
$-25.08 (-3.70%)
Day High
$677.85
Day Low
$650.95
Day Open
$677.85
Prev Close
$677.56
Volume
80,724
1W Return
-0.27%
1M Return
4.91%
3M Return
11.62%
6M Return
57.76%
1Y Return
11.62%
Fundamentals
Market Cap ($ Mn)
18,251
PE Ratio
35.27
PB Ratio
38.64
PEG Ratio
1.19
ROE
96.22%
ROCE
82.15%
EPS (TTM)
$4.92
Investment Returns
1 Week
-0.27%
1 Month
4.91%
3 Months
11.62%
6 Months
57.76%
9 Months
10.02%
Financials
Quarterly
All values in $ Mn
603.3
Jun 25
659.9
Sep 25
708.5
Dec 25
706.6
Mar 26
707.3
Jun 26
716.0
Sep 26
Updates
22Oct
Medpace Holdings Q3 results: EPS up 25% YoY to $4.84, revenue rises 8.5%
Medpace Holdings reported Q3 2026 EPS of $4.84, beating consensus estimates by 9.01%. Revenue rose 8.5% YoY to $716 million, with EBITDA margin expanding to 24.0%. Net new business awards increased 10.6% to $873.4 million; backlog stands at $3.17 billion. Company announced a new $1.0 billion share repurchase authorization effective October 2026.
8 days ago
22Oct
Medpace Holdings terminates old buyback, approves new $1B repurchase
Medpace Holdings terminated its existing share buyback authorization. Approved a new $1 billion share repurchase program. New buyback authority is valid through 2028.
8 days ago
22Oct
Medpace Holdings raises FY26 EPS guidance to $17.97-$18.32
Medpace Holdings raises FY26 GAAP EPS guidance to $17.97-$18.32 from $17.25-$17.95. New EPS range exceeds the analyst estimate of $17.60. FY26 sales guidance narrowed to $2.835B-$2.855B from $2.805B-$2.885B. Revised sales outlook aligns closely with the $2.851B analyst estimate.
8 days ago
7Oct
Barclays lifts Medpace price target to $625, keeps Equal-Weight
Barclays raised Medpace Holdings' price target to $625 from $600. The firm maintained an Equal-Weight rating on the stock. Analyst Luke Sergott issued the revised price objective.
23 days ago
30Sep
Medpace Holdings: $100 invested a decade ago now worth $2,048
A $100 investment in Medpace Holdings 10 years ago is now worth $2,048.90. The stock delivered an average annual return of 35.51% over the past decade. Medpace Holdings outperformed the market by 21.9% on an annualized basis. Current share price is $624.00 with a market cap of $17.42 billion.
1mo ago
23Sep
Medpace Holdings Q3FY26 Results: Earnings call set for Oct 22
Medpace Holdings to report Q3FY26 results after market close on October 21, 2026. Conference call scheduled for 9:00 am ET on October 22, 2026. Webcast and supplemental slides available via investor.medpace.com. Company employs ~6,500 people across 46 countries as of June 30, 2026.
